



## ASX Company Announcement

### DR ANTON UVAROV TO BE APPOINTED AS A NON-EXECUTIVE DIRECTOR

25 October 2013

---

The Board of Sun Biomedical Limited (ASX: SBN) is pleased to announce that Dr Anton Uvarov is to be appointed to the Board as Non Executive Director following the Annual General meeting to be held on 20 November 2013.

Dr Uvarov has extensive worldwide knowledge of the medical device sector, which will be invaluable in the implementation of the Company's strategy to commercialise the Oraline drug testing device. He also brings considerable experience in the pharmaceutical, biotechnology and life sciences sector to the SBN Board.

Dr Uvarov is a senior equities analyst with a focus on healthcare and biotechnology sector based in Perth, Western Australia. Prior to coming to Australia, he was with Citigroup Investment Research where he spent two years as a member of New York based healthcare and biotechnology team.

At Citigroup, Dr Uvarov was covering small to mid cap biotechnology companies, vetting public and private companies and providing recommendations to Citigroup's investment banking division. He has a deep knowledge of healthcare industry including intellectual property, FDA and EMA regulations, reimbursement coverage, and clinical science. Dr Uvarov also has a broad experience of working with leading US institutional clients as a part of his research mandate at Citigroup.

Dr Uvarov holds a PhD degree from the University of Manitoba, Canada and an MBA degree from the University of Calgary, Canada. He obtained his undergraduate degree in Biochemistry and Molecular Biology from Moscow State University. Dr Uvarov has also co-authored several peer-reviewed publications on the mechanisms of intracellular protein degradation and its role in cancer and cardiovascular diseases.

Howard Digby  
Chairman